All In Biotech

Drug Trial Radar · NCT06132932

A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390, a PI3K/mTOR Dual Inhibitor, for the Treatment of Advanced Solid Tumors With PIK3CA Mutations

Last checked: Nov 19, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Jun 3, 2021

Primary completion

Jan 3, 2023

Study completion Jan 3, 2023

Sponsor

Sponsor type
Industry
First posted
Nov 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 in patients with advanced solid tumors. The main question it aims to answer is: • safety and preliminary efficacy in WX390 therapy. Participants will be treated with WX390 orally and follow the efficacy and safety evaluation according to the protocol.

Conditions

  • PIK3CA Mutation-Related Tumors

Interventions

  • WX390Drug

    Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of WX390 in treating patients with advanced malignant solid tumors harboring PIK3CA mutations.Time frame: From the start of the trial,up to 24 weeks
  2. Objective Response Rate (ORR)Time frame: From the start of the trial,up to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.